Vaxiion Therapeutics   Report issue

For profit Phase 1
Founded: San Diego CA United States (2000)

Organization Overview

First Clinical Trial
2019
NCT03854721
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Vaxiion Therapeutics

Active Ingredients

Drugs in Phase 1 Trials (1)

vax014 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Transitional Cell (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1